# Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation

> **NCT05153395** · EARLY_PHASE1 · SUSPENDED · sponsor: **University of Missouri-Columbia** · enrollment: 65 (estimated)

## Conditions studied

- Healthy
- Vasodilation
- Insulin Resistance
- Autonomic Dysfunction
- Obesity

## Interventions

- **OTHER:** Carbon dioxide breathing
- **OTHER:** Neurovascular Coupling
- **DRUG:** Human insulin

## Key facts

- **NCT ID:** NCT05153395
- **Lead sponsor:** University of Missouri-Columbia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-12-01
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 65 (ESTIMATED)
- **Why stopped:** Interim data and power analysis
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153395, "Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05153395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*